Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma Plc LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -1.18% 84.00 83.90 84.00 85.00 83.90 85.00 5,125,613 16:29:49
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 135.6 32.9 5.1 16.5 447

Alliance Pharma PLC Block Listing Six Monthly Return

29/12/2020 12:43pm

UK Regulatory (RNS & others)


TIDMAPH

RNS Number : 0314K

Alliance Pharma PLC

29 December 2020

 
 For immediate release   29 December 2020 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

 
 Name of applicant:                                     ALLIANCE PHARMA PLC 
 Names of schemes:                                      a) The Alliance Pharma plc Approved Share Option Plan 2005 
                                                         b) The Alliance Pharma plc Share Option Plan 2006 
                                                         c) The Alliance Pharma plc Company Share Option Plan 2015 
                                                       --------------------------------------------------------------- 
 Period of return:              From:                   28 June 2020             To:      28 December 2020 
                               ----------------------  -----------------------  -------  ----------------------------- 
 Number of securities originally admitted at date of    25,000,000 ordinary shares of 1p each 
 admission:                                              28 June 2017 
                                                       --------------------------------------------------------------- 
 Balance of unallotted securities under schemes from    a) 356,536 
 previous return:                                        b) 5,362,778 
                                                         c) 14,923,223 
                                                       --------------------------------------------------------------- 
 Plus: The amount by which the block schemes have       a) Nil 
 been increased since the date of the last               b) Nil 
 return (if any increase has been applied for):          c) Nil 
                                                       --------------------------------------------------------------- 
 Less: Number of securities issued/allotted under        a) 63,164 
 schemes during period:                                   b) 96,156 
                                                          c) 1,701,727 
                                                       --------------------------------------------------------------- 
 Equals: Balance under schemes not yet                  a) 293,372 
 issued/allotted at end of period:                       b) 5,266,622 
                                                         c) 13,221,496 
                                                       --------------------------------------------------------------- 
 
 
 
 Name of contact:               Chris Chrysanthou, Company Secretary 
 Telephone number of contact:   Tel. +44 (0)1249 705166 
                               ------------------------------------- 
 

For further information:

Alliance Pharma plc + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

Buchanan + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

Investec Bank plc +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRKKCBQBBDDKBB

(END) Dow Jones Newswires

December 29, 2020 07:43 ET (12:43 GMT)

1 Year Alliance Pharma Chart

1 Year Alliance Pharma Chart

1 Month Alliance Pharma Chart

1 Month Alliance Pharma Chart
ADVFN Advertorial
Your Recent History
LSE
APH
Alliance P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210303 23:43:58